U.S. Markets close in 4 hrs 40 mins

CEL-SCI Corporation (CVM)


NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
1.955-0.03 (-1.76%)
As of 11:03AM EDT. Market open.
People also watch
HEBCYTRCTICAGENGNBT
  • The Multikine safety problem that Kyle seeks to deny.

    The FDA says the Multikine trial places patients at an unreasonable and substantial risk of injury. The trial's IDMC wrote to Cel Sty in 2016 that it was seriously concerned over patient safety after eviewing the cumulative trial data.

    In the trial, enrolled patients get standard care or Multikine plus standard care (with or without CIZ). So, if there's a major safety issue as both FDA and the IDMC say, what is causing that? Standard care (yeah, so standard care is a hazard which is why it is the standard! LOL!)? The answer is obviously that Multikine is the source of the safety issue.

    Slippery Kyle insists that Multikine s not the problem, but that that Multikine's safety problems (and lack of afficacy) all stem from inVentiv's a;eged mismanagement of the patients that it enrolled in the trial.

    How did inVenitv supposedly mismanage patients?Geerty alleges that inVentiv gave Multikine to the wrong patients, administerd Multikine incorrectly, enolled patients who didn't meet the enrollment criteria,etc.

    How would any of these actions lead to a srious side effect? Multikine injected to a wrong site is toxic, but Multikine injected into the proper site is not? Multikine injected into a head and neck cance patient who shouldn't have received it because he was assigned to the control group is toxic, but Multikine is perfectly safe in a patient assigned to the treatment arm of the trial?

    Kyle's explanations are pure nonsense!

    Further, the IDMC recommended to CVM that it shut down the trial in 2014 for both safety and toxicity issues. Geerty intervened, and the IDMC relented. But again in 2016, the IDMC recommended closing the trial to new enrollment and wrote to Cel Sty that it was seriously concerned over patient safety based on the cumulative data.

    Slippery Kyle insists that all of this is attributable to inVentiv's trial mismanagement, not any property of Multikine. But inVentiv was fired in 2013. So Kyle basically is positing the absurd notion that inVentiv adminstering Multikine incorrectly or to the wrong patients in 2013 disappeared for two years and then suddenly resurfaced in 2016.

    Preposterous!
  • So is Geert's $250K investment for real or just another ploy? I have no clue how to view it.
  • Desperation time in Geertyville! The huckster can't even play the old pump and dump anymore.

    Multikine has failed, as is abundantly clear from CVM's SEC filings; the FDA told it that it should end the PhIII trial for futility, that the protocol couldn't achieve its stated objective of proving that adding Multikine to standard car improves survival and that there is no way to fix the protocol, and that Multikine poses a serious and unreasonable risk to patients. It's so bad that geerty had to pull his proposed trial amendment, in which he wanted to expand the trial by nearly 50% and drop the threshold for success by 35%, and he's now left playing out the string -- which will cost another $13 million when Cel Sty can raise only enough money every quarter to keep the lights on.

    This POS is done!
  • I knew if I got out it would go up. I hope it continues but a little jealous.
  • Johnny,

    So how does this new GEERTY Pump and dump work?

    I mean I thought Geert's goal was to steal from CVM investers?

    Now he's investing $250,000 in CVM?
  • Hey Pap Smear I just liked my own comment!! You can't bring me down today with your anger and negativity!! I'm gonna poop again just for you!! Geez, lighten up imbecile.
  • all in dxtr now buy out $1.5
  • Settlement!
  • rather go to Vegas and gamble then buy this lol
  • Anyone seen Johnny Casssandra?
  • Does anyone know the record for fasted drop from $2 to $1 after a R/S with no other bad news on a listed company? Is CVM trying to set this record? I would imagine we could see $1 by Friday, so that might qualify as a new record...
  • I'm the last one who still believes!! Johnny don't you dare poop on my parade!!!
  • If it ends above $2 next stop $5!!! I feel it!! Pap Smear stop being a downer!!;
  • CEO PURCHASED a cool quarter million dollars worth. I do not care what Johnny says because it does not make sense. .I am out for now but watching closely.
  • I'm getting that feeling again!!! And I didn't eat Thai all weekend!!
  • We need a PTLA like day...their blood thinner drug was approved by FDA thing rocketed up from 38 to 56 yesterday.
  • The quiet accumulation of warrants tells a story. They aren't being purchase by retail investors.
  • BTW: Arbitration hearing expected to end late June.

    ALSO: ARB has ***NOT*** been extended 6 months.
  • DO YOU GET INTEREST PAYMENTS WHEN YOU BUY SHARES HERE? LMAO!!! WHY WOULD YOU BUY STOCK IN A COMPANY THAT HAS A LIEN ON ALL THEIR ASSETS? REALLY LMAO,,,YOU ARE GOOD SUCKERS....WHAT ABOUT THIS TOO???

    THEY HAVE ZERO REVENUE PLUS DID YOU READ THE SEC FILINGS? PHASE 3 IS COMPLETELY SHUT DOWN

    """"""The heading on the FDA May 2017 letter is “Continue Full Clinical Hold”, whereas the heading on previous hold letters was “Partial Clinical Hold”. """""""

    """the IDMC made a recommendation that the study be closed for safety and efficacy reasons""""
  • At this point, the RS may be a very good strategy.
    If Arbitration is positive,and the Clinical Hold is lifted, and Price stays over $2.00 Institutions will pay more attention and send this over $10.00. Approval of MultiKine could make this a $50 Stock easily. ACCUMULATE